Stat6

Contents: Stat6 (C19) Blocking Peptide
Catalog Number: 66-P735
Formulation: Each vial contains 100 μg of peptide in 0.5 ml PBS with 0.1% NaN₃ and 100 μg BSA.
Storage Conditions: Store at 4°C.
DO NOT FREEZE.

Prices for This Product*
Cat. No.	Size	Price	Qty	Action
66-P735-81	50 ug	$25

*International customers: Please contact your distributor for region specific pricing.

Available Formats of This Product
Cat. No.	Format	Excite (nm)	Emit (nm)	Reported Applications
66-P735	Blocking Peptides for anti-human Stat6 polyclonal	N/A	N/A	WB

Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq.

Description

This is a peptide mapping to the carboxy terminus of human Stat6. Signal Transducers and Activators of Transcription (STATs) are a family of cytoplasmic proteins that participate in cellular responses to cytokines and growth factors (1). Many cytokines involved in immune responses utilize the Jak-STAT signaling pathway. Jaks are receptor-associated protein tyrosine kinases, and STATs are activated by tyrosine phosphorylation (2). Abnormal signaling of the JAK-STAT pathway has been implicated in hematopoietic disorders including severe combined immunodeficiency and leukemia (4). STATs have been implicated in programming gene expression in biological events such as embryonic development, programmed cell death, organogenesis, innate immunity, adaptive immunity and cell growth regulation in many organisms (3). STAT1 knockout mice are defective in interferon-mediated functions. STAT4 and STAT6 knockout mice show defective responses to IL-12 and IL-4, respectively. Analyses of STAT5a and STAT5b knockout mice reveal important roles in prolactin-mediated mammary gland development and growth hormone-mediated induction of sexual dimorphism, respectively. Conditional knockout study of STAT3 demonstrates its critical roles in cytokine-mediated functions in several tissues, including T cells, macrophages, skin, and mammary gland (5). Abnormal activity of certain STAT family members, particularly STAT3 and STAT5, is associated with a wide variety of human malignancies, including hematologic, breast, head and neck, and prostate cancers (1). STAT5A and STAT6, are selectively activated when the heart is subjected to ischemic injury, whereas activation of STAT3 and STAT5A is involved in myocardial hypertrophy (6), (7).

Applications Reported

For research use only, not for diagnostic or therapeutic use. This blocking peptide has been reported for use in competition studies.

References

1. Turkson J, Jove STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000 Dec 27; 19(56): 6613-26.
2. Ivashkiv LB. Jak-STAT signaling pathways in cells of the immune system. Rev Immunogenet. 2000; 2(2): 220-30
3. Horvath CM. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci. 2000 Oct; 25(10): 496-502.
4. Nosaka T, Kitamura T. Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) in hematopoietic cells. Int J Hematol. 2000 Jun; 71(4): 309-19.
5. Takeda K, Akira S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev. 2000 Sep; 11(3): 199-207.
6. Mascareno E, Siddiqui MA. The role of Jak/STAT signaling in heart tissue renin-angiotensin system. Mol Cell Biochem. 2000 Sep; 212(1-2): 171-5.
7. Mascareno E, El-Shafei M, Maulik N, Sato M, Guo Y, Das DK, Siddiqui MA. JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation 2001 Jul 17;104(3):325-9.

Related Products

Cat. 14-6735 Purified anti-human Stat6 polyclonal (clone Polyclonal)